A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
A phase 1/2 trial of Two IM injections Lenti-HPV-07 in cervical cancer and head and neck squamous cell carcinoma, run by Theravectys S.A., now recruiting.
Overview
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer is a phase 1/2 interventional study registered as NCT06319963 by Theravectys S.A., with 72 participants planned, started 2024-08-08 and due to reach its primary completion in 2026-06. Interventions recorded: Two IM injections Lenti-HPV-07 and One IM injection Lenti-HPV-07.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
Shares Cervical cancer and the tag pipeline.
- TrialMIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialFID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialTo Evaluate the Efficacy and Safety of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) Combined With NBB-001 and NBB-002 for Patients With Recurrent Head and Neck Malignancies
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Study of IDP-001 in Advanced or Metastatic Solid Tumors
Shares Cervical cancer, Head and neck squamous cell carcinoma and the tag pipeline.
- TrialPRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Shares Cervical cancer and the tag pipeline.
- TrialA Study of DM005 in Patients With Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma and the tag pipeline.